TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17650211

Group type: EXPERIMENTAL
Intervention: Synbiotic milk (Lactobacillus acidophilus strain 74‐2, 10(7) CFU ml(‐1), Bifidobacterium lactis strain 420, 10(7) CFU ml(‐1), 2% inulin) consumed for 4 weeks at 500 ml day(‐1)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (2% skimmed milk) consumed for 4 weeks at 500 ml day(‐1)
Number of subjects: 26
Study: 16510462

Group type: EXPERIMENTAL
Intervention: Medical therapy
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Surgical therapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (surgery)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both treatments (medical and surgical)
Number of subjects: 90
Study: 14634938

Group type: EXPERIMENTAL
Intervention: Triple-injection axillary brachial plexus block (group A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Humeral approach (group H)
Number of subjects: 100
Study: 10783203

Group type: EXPERIMENTAL
Intervention: Tissue plasminogen activator
Number of subjects: 30510

Group type: COMPARATOR
Intervention: Streptokinase thrombolytic therapy
Number of subjects: 30510

Group type: EXPERIMENTAL
Intervention: Tissue plasminogen activator (adjusted for age)
Number of subjects: 30510

Group type: EXPERIMENTAL
Intervention: Tissue plasminogen activator (adjusted for 17 characteristics)
Number of subjects: 30510
Study: 8626832

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GnRH
Number of subjects: 0
Study: 1426302

Group type: EXPERIMENTAL
Intervention: Surgical assessment of resectability
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Diagnostic methods for resectable tumours
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Positive predictive values in resectable disease
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Positive predictive values in unresectable disease
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Average macroscopic diameter of resectable tumours
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Factors influencing resectability
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Radical pancreatic surgery
Number of subjects: 472
Study: 4044777

Group type: EXPERIMENTAL
Intervention: 4 micrograms/day estradiol infusion
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 20 micrograms/day estradiol infusion
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 90 micrograms/day estradiol infusion
Number of subjects: 5
Study: 31848172

Group type: EXPERIMENTAL
Intervention: Intralesional steroid injection followed by balloon dilatation
Number of subjects: 110

Group type: COMPARATOR
Intervention: Dilatation only
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Intralesional steroid injection
Number of subjects: 110
Study: 29063390

Group type: EXPERIMENTAL
Intervention: 2-year treatment group (2YG, N = 112)
Number of subjects: 222

Group type: COMPARATOR
Intervention: 3-or-more-year treatment group (3YG, N = 110)
Number of subjects: 222
Study: 27002857

Group type: EXPERIMENTAL
Intervention: Balloon Eustachian tuboplasty (BET) during planned surgery
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no BET)
Number of subjects: 100
Study: 24284387

Group type: EXPERIMENTAL
Intervention: 8-12-week treadmill exercise program (target lactate 2.0±0.5 mmol l(‐1))
Number of subjects: 72

Group type: COMPARATOR
Intervention: Sedentary control
Number of subjects: 72
Study: 23158112

Group type: EXPERIMENTAL
Intervention: Group‐Mediated Cognitive Behavioral (GMCB) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Health education control condition
Number of subjects: 0
Study: 19851869

Group type: EXPERIMENTAL
Intervention: High quality metaphorical pairings
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low quality metaphorical pairings
Number of subjects: 0
Study: 19032235

Group type: EXPERIMENTAL
Intervention: Grazax
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study: 16118817

Group type: EXPERIMENTAL
Intervention: Insecticide spray
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Latrine provision
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 0
Study: 12014417

Group type: EXPERIMENTAL
Intervention: 2% lidocaine jelly
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nonmedicated lubricant (control)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Anoscopy
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy without anoscopy
Number of subjects: 50
Study: 10418840

Group type: EXPERIMENTAL
Intervention: Botulinus toxin Type A (400 mouse units injected into calf muscles)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Phenol (3 ml of 5% phenol for tibial nerve blockade)
Number of subjects: 20
Study: 8847032

Group type: EXPERIMENTAL
Intervention: 20mg Omeprazole daily + 500mg Amoxicillin qid
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: 20mg Omeprazole bid + 500mg Amoxicillin qid
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: 20mg Omeprazole tid + 500mg Amoxicillin qid
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: 20mg Omeprazole qid + 500mg Amoxicillin qid
Number of subjects: 73

Group type: COMPARATOR
Intervention: H. pylori positive patients
Number of subjects: 73

Group type: COMPARATOR
Intervention: H. pylori negative patients
Number of subjects: 73
Study: 1962776

Group type: EXPERIMENTAL
Intervention: Technetium-labeled monoclonal antibody
Number of subjects: 52

Group type: COMPARATOR
Intervention: CT and histologic confirmation
Number of subjects: 52
Study: 6106739

Group type: EXPERIMENTAL
Intervention: Electrostatic precipitator used during the night
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control period (no electrostatic precipitator)
Number of subjects: 10
Study: 29746133

Group type: EXPERIMENTAL
Intervention: Generic formulation X2
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Generic formulation X1
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Test formulation Y1
Number of subjects: 4

Group type: COMPARATOR
Intervention: In vitro dissolution experiment
Number of subjects: 4
Study: 28104073

Group type: EXPERIMENTAL
Intervention: Ablation at dispersion areas
Number of subjects: 105

Group type: COMPARATOR
Intervention: Conventional ablation approach (validation set)
Number of subjects: 105
Study: 25800496

Group type: EXPERIMENTAL
Intervention: Umbilical Cord Milking (UCM)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Delayed Cord Clamping (DCC)
Number of subjects: 200
Study: 24062178

Group type: EXPERIMENTAL
Intervention: 4CMenB vaccine (5th dose)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (MenB vaccine-naive participants receiving 4CMenB)
Number of subjects: 57
Study: 21959035

Group type: EXPERIMENTAL
Intervention: Electromechanical orthosis training
Number of subjects: 12

Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 12
Study: 18379855

Group type: EXPERIMENTAL
Intervention: CABG in patients with unstable angina pectoris (group I)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: CABG in patients with non-ST-elevation infarction (group II)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: CABG in patients with ST-elevation infarction (group III)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Overall CABG in patients with ACS
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Time from onset of symptoms to revascularization in STEMI group
Number of subjects: 220
Study: 16855778

Group type: EXPERIMENTAL
Intervention: Suprapubic method
Number of subjects: 23

Group type: COMPARATOR
Intervention: Transurethral method
Number of subjects: 23
Study: 14600189

Group type: EXPERIMENTAL
Intervention: Long-acting beta2-agonists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tiotropium (anticholinergic)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of long-acting beta2-agonist and inhaled corticosteroid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Domiciliary oxygen therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Disease management programs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Noninvasive mechanical ventilation
Number of subjects: 0
Study: 10973647

Group type: EXPERIMENTAL
Intervention: Immediate mobilization after IUI (group I)
Number of subjects: 116

Group type: COMPARATOR
Intervention: 10 minutes of bed rest after IUI (group II)
Number of subjects: 116
Study: 8977745

Group type: EXPERIMENTAL
Intervention: 40 mg/day carbimazole
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 20 mg/day carbimazole
Number of subjects: 63
Study: 1334465

Group type: EXPERIMENTAL
Intervention: DDD pacing with short AVD (100 ms)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: DDD pacing with long AVD (150 ms)
Number of subjects: 13

Group type: COMPARATOR
Intervention: VVI pacing
Number of subjects: 13
Study: 6721539

Group type: EXPERIMENTAL
Intervention: Topically applied technical fenvalerate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heavy‐ends fraction of fenvalerate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ethyl alcohol (vehicle)
Number of subjects: 0
Study: 31939583

Group type: EXPERIMENTAL
Intervention: Home physical exercise program (10 weeks)
Number of subjects: 52
Study: 30516259

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) administered intravenously to Group A
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 70
Study: 27654971

Group type: EXPERIMENTAL
Intervention: AZD8931 20 mg + anastrozole
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: AZD8931 40 mg + anastrozole
Number of subjects: 359

Group type: COMPARATOR
Intervention: Placebo + anastrozole
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: AZD8931 20 mg
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: AZD8931 40 mg
Number of subjects: 359

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 359
Study: 25034315

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (2,000 IU/day)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 22728647

Group type: EXPERIMENTAL
Intervention: Guided internet-delivered cognitive behaviour therapy (ICBT)
Number of subjects: 174
Study: 20797774

Group type: EXPERIMENTAL
Intervention: Short thromboprophylaxis (stopping at Day 10±2)
Number of subjects: 857

Group type: COMPARATOR
Intervention: Extended thromboprophylaxis (continuing up to Day 35±5)
Number of subjects: 857

Group type: EXPERIMENTAL
Intervention: Short thromboprophylaxis (in patients with asymptomatic distal deep-vein thrombosis)
Number of subjects: 857

Group type: COMPARATOR
Intervention: Extended thromboprophylaxis (in patients with asymptomatic distal deep-vein thrombosis)
Number of subjects: 857

Group type: EXPERIMENTAL
Intervention: Short thromboprophylaxis
Number of subjects: 857

Group type: COMPARATOR
Intervention: Extended thromboprophylaxis
Number of subjects: 857
Study: 17727981

Group type: EXPERIMENTAL
Intervention: Oral-appliance therapy
Number of subjects: 28

Group type: COMPARATOR
Intervention: CPAP therapy
Number of subjects: 28
Study: 16911345

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (1200 mg/day)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study: 14622683

Group type: EXPERIMENTAL
Intervention: Visual Analog Scale (VAS) ratings of 0 to 4 mm
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Visual Analog Scale (VAS) ratings of 5 to 44 mm
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Visual Analog Scale (VAS) ratings of 45 to 74 mm
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Visual Analog Scale (VAS) ratings of 75 to 100 mm
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Percentage change in VAS score
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: 33% decrease in pain
Number of subjects: 248
Study: 11703619

Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg
Number of subjects: 364

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 364
Study: 9129477

Group type: EXPERIMENTAL
Intervention: Calcium supplement (1000 mg supplemental Ca/d as calcium citrate malate)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 8198899

Group type: COMPARATOR
Intervention: Control (carrier gas)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 0.04 MAC enflurane
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 0.07 MAC enflurane
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 0.13 MAC enflurane
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 0.07 MAC enflurane (Design 2)
Number of subjects: 12
Study: 3444801

Group type: EXPERIMENTAL
Intervention: Alternate day corticosteroid treatment
Number of subjects: 0
Study: 30338694

Group type: EXPERIMENTAL
Intervention: Ear protectors
Number of subjects: 24

Group type: COMPARATOR
Intervention: No ear protectors (control)
Number of subjects: 24
Study: 30715100

Group type: COMPARATOR
Intervention: Blood pressure treatment goal
Number of subjects: 4268
Study: 28969626

Group type: EXPERIMENTAL
Intervention: AyuFlex1 (250 mg twice daily)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: AyuFlex2 (500 mg twice daily)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 25277305

Group type: EXPERIMENTAL
Intervention: 2.0 mg intravitreal ranibizumab injections
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.5 mg intravitreal ranibizumab injections
Number of subjects: 0
Study: 23513061

Group type: EXPERIMENTAL
Intervention: Short-duration transient visual evoked potential (SD-tVEP)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Low contrast (Lc) SD-tVEP
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: High contrast (Hc) SD-tVEP
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: SD-tVEP
Number of subjects: 75
Study: 21744187

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 28

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 28
Study: 19143691

Group type: EXPERIMENTAL
Intervention: 4 mg ondansetron
Number of subjects: 5161

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5161
Study: 16112244

Group type: EXPERIMENTAL
Intervention: Lisinopril (20 mg once daily for 24 weeks)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Telmisartan (80 mg once daily for 24 weeks)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Lisinopril plus Telmisartan (after 24 weeks of monotherapy for an additional 28 weeks)
Number of subjects: 192
Study: 15312391

Group type: EXPERIMENTAL
Intervention: Intraperitoneal hyperthermic chemoperfusion (IHCP) combined with intravenous chemotherapy
Number of subjects: 82

Group type: COMPARATOR
Intervention: Intravenous chemotherapy only
Number of subjects: 82
Study: 11783600

Group type: EXPERIMENTAL
Intervention: Benazepril (0.2 mg/kg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9129478

Group type: EXPERIMENTAL
Intervention: Moderate protein (MP; 23 g)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Moderate protein plus potassium bicarbonate (MP+K; 23 g + 23 mmol KHCO3)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High protein (HP; 53 g)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High protein plus potassium bicarbonate (HP+K; 53 g + 70 mmol KHCO3)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High protein plus sodium chloride (HP+Na; 53 g + 70 mmol NaCl)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Moderate protein plus phosphate (MP+Pi; 23 g + 7.5 mmol phosphate)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Moderate protein (MP)
Number of subjects: 20
Study: 8498389

Group type: EXPERIMENTAL
Intervention: Health promotion program (low-cost, $30/year, individualized, delivered through mail)
Number of subjects: 4712

Group type: COMPARATOR
Intervention: Risk appraisals only (first 12 months) then full intervention (second 12 months)
Number of subjects: 4712

Group type: COMPARATOR
Intervention: Claims data only (control group)
Number of subjects: 4712
Study: 31603106

Group type: EXPERIMENTAL
Intervention: Breast Conservation Therapy (BCT)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Modified Radical Mastectomy (MRM)
Number of subjects: 170
Study: 30392341

Group type: EXPERIMENTAL
Intervention: HPV testing
Number of subjects: 63931

Group type: EXPERIMENTAL
Intervention: Cytology
Number of subjects: 63931

Group type: EXPERIMENTAL
Intervention: Visual inspection via acetic acid or Lugol's iodine (VIA/VILI)
Number of subjects: 63931

Group type: COMPARATOR
Intervention: HPV positive group
Number of subjects: 63931

Group type: COMPARATOR
Intervention: Cytology-positive group
Number of subjects: 63931
Study: 27265844

Group type: EXPERIMENTAL
Intervention: Testosterone gel (TRT, n = 20)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo (n = 19)
Number of subjects: 39
Study: 24940942

Group type: EXPERIMENTAL
Intervention: 2 SPMC sachets (split doses)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 3 SPMC sachets (split doses)
Number of subjects: 200

Group type: COMPARATOR
Intervention: 4 L PEG in the morning on the day of colonoscopy
Number of subjects: 200

Group type: COMPARATOR
Intervention: 2 L split doses of PEG
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: All groups (SPMC and PEG)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: SPMC
Number of subjects: 200
Study: 23041738

Group type: EXPERIMENTAL
Intervention: HES 130/0.4
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: HES 130/0.42
Number of subjects: 52
Study: 20175411

Group type: EXPERIMENTAL
Intervention: Variable-pressure CPAP
Number of subjects: 200

Group type: COMPARATOR
Intervention: Fixed-pressure CPAP
Number of subjects: 200
Study: 18627321

Group type: EXPERIMENTAL
Intervention: Tramadol ER 100 mg
Number of subjects: 2031

Group type: EXPERIMENTAL
Intervention: Tramadol ER 200 mg
Number of subjects: 2031

Group type: EXPERIMENTAL
Intervention: Tramadol ER 300 mg
Number of subjects: 2031

Group type: EXPERIMENTAL
Intervention: Tramadol ER 400 mg
Number of subjects: 2031

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2031
Study: 16149140

Group type: EXPERIMENTAL
Intervention: American ginseng (AG) supplementation for 4 weeks
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo supplementation for 4 weeks
Number of subjects: 13
Study: 11933558

Group type: EXPERIMENTAL
Intervention: Omapatrilat
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lisinopril
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 0
Study: 10418911

Group type: EXPERIMENTAL
Intervention: DTPa (Infanrix, SmithKline Beecham, Biologicals)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Reduced antigen formulation (dtpa, SmithKline Beecham Biologicals)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Experimental low dose formulation (dtpa-exp; d and t, Michigan Biologic Products Institute)
Number of subjects: 226
Study: 7560662

Group type: EXPERIMENTAL
Intervention: Bradykinin
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Hypertonic saline
Number of subjects: 11
Study: 2405089

Group type: EXPERIMENTAL
Intervention: Controlled-release metoprolol 200 mg once daily
Number of subjects: 22

Group type: COMPARATOR
Intervention: Atenolol 100 mg once daily
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo run-in period
Number of subjects: 22
Study: 7403993

Group type: EXPERIMENTAL
Intervention: econazole (Ecostatin; Squibb) for 7 days
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: econazole (Ecostatin; Squibb) for 14 days
Number of subjects: 330
Study: 30335191

Group type: COMPARATOR
Intervention: Trastuzumab and/or lapatinib during gestation (exposed group)
Number of subjects: 92

Group type: COMPARATOR
Intervention: No trastuzumab and/or lapatinib during gestation (unexposed group)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Pregnant patients (n = 85)
Number of subjects: 92
Study: 29128712

Group type: EXPERIMENTAL
Intervention: Personalized feedback intervention
Number of subjects: 109

Group type: COMPARATOR
Intervention: Assessment-only control (AOC)
Number of subjects: 109
Study: 27230875

Group type: EXPERIMENTAL
Intervention: Rotational Atherectomy + Cutting Balloon (RA + CB)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Rotational Atherectomy (RA)
Number of subjects: 71
Study: 24298947

Group type: COMPARATOR
Intervention: Non-ST elevation myocardial infarction (non-STEMI) patients
Number of subjects: 102

Group type: COMPARATOR
Intervention: Stable angina (SA) patients
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Healthy controls
Number of subjects: 102

Group type: COMPARATOR
Intervention: Patients with sustained NK cell deficit
Number of subjects: 102

Group type: COMPARATOR
Intervention: Patients with pronounced increase in NK cells
Number of subjects: 102

Group type: COMPARATOR
Intervention: Patients with failure to reconstitute NK cell levels
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: All patients during 12-month follow-up
Number of subjects: 102
Study: 22294704

Group type: EXPERIMENTAL
Intervention: Five-fraction schedule of whole-breast radiotherapy following local excision of early breast cancer
Number of subjects: 915
Study: 19961336

Group type: EXPERIMENTAL
Intervention: Baseline bone turnover markers (S-TRACP5b)
Number of subjects: 1040

Group type: EXPERIMENTAL
Intervention: Baseline bone turnover markers (S-CTX-I)
Number of subjects: 1040

Group type: EXPERIMENTAL
Intervention: Urinary osteocalcin (measured at 1-year visit)
Number of subjects: 1040

Group type: EXPERIMENTAL
Intervention: Resorption markers (average of two measurements)
Number of subjects: 1040

Group type: EXPERIMENTAL
Intervention: S-TRACP5b, S-CTX-I, and urinary osteocalcin
Number of subjects: 1040
Study: 17503039

Group type: EXPERIMENTAL
Intervention: FDG-PET/CT before and after neo-adjuvant CRT
Number of subjects: 48
Study: 16376765

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Ratio of early mitral inflow velocity to mitral annular velocity
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Baseline heart rate
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Plasma levels of B-type natriuretic peptide
Number of subjects: 73
Study: 11926722

Group type: EXPERIMENTAL
Intervention: Duloxetine (titrated from 40 mg to 120 mg/day)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Fluoxetine, 20 mg q.d.
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 173